Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05933174 · ClinicalTrials.gov registry record · NA
Promoting Alternatives to Sulfonylureas to Improve Patient Safety in Type 2 Diabetes
A NA study of Type2diabetes, sponsored by Ian J. Neeland, MD.
- Recruiting
- Registry status
- NA
- Development phase
- 220
- Enrollment target
- 1
- Study location
NCT05933174 is a NA study of Type2diabetes that is actively recruiting participants, run by Ian J. Neeland, MD. The registered enrollment target is 220 participants, below the 483-participant average among 19 other Type2diabetes trials with a reported enrollment target (54% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05933174, a NA study of Type2diabetes, is actively recruiting participants, sponsored by Ian J. Neeland, MD.
- RECRUITING
- Registry status
- NA
- Development phase
- 220 participants
- Enrollment target
- 1
- Study location
Study Summary
Sulfonylurea medications are unsafe for older patients with diabetes. They are associated not only with hypoglycemia, but also with falls and increased cardiovascular risk. Yet they continue to be prescribed frequently. Indeed, older adults with type 2 diabetes, who are especially prone to adverse effects, are more likely to be prescribed sulfonylureas than younger patients. This is unfortunate since over the past several years, newer, safer, and more effective classes of medications (GLP-1 agonists and SGLT2-inhibitors) have emerged. The investigators acknowledge that sulfonylureas are inexpensive and that their low cost is a driver of continued use. However, the investigators believe patients and providers should have discussions about the risks of sulfonylureas and safer and more effective alternatives, to make diabetes care safer overall in ambulatory settings. Our research is designed to promote such discussions. The investigators will first identify patients taking sulfonylureas regularly. Next, using recommendations from AHRQ and the Canadian Deprescribing Network, the investigators will empower patients to discuss their medications with their providers through a simple question prompt sheet. Patients will be divided into an intervention group which receives explicit prompting questions, and a control group that receives a general brochure on diabetes medications. Health care providers will receive education about newer diabetes medications through case-based discussions and academic detailing. Finally the investigators will measure key outcomes including the proportion of patients who have discussions about sulfonylureas and alternatives, rates of discontinuation, and measures of control of diabetes and associated cardiovascular risks. The investigators will also evaluate the experiences of patients and providers qualitatively through brief, semi-structured interviews. Should our multi-faceted, patient-oriented intervention prove effective in promoting discu
Conditions Studied
Interventions
- OTHER Prompt-sheet
- OTHER Usual education
Study Locations (1)
Ohio
- University Hospitals Cleveland Medical Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2023-10-01 |
| Est. Completion | 2026-06-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05933174
The ClinicalTrials.gov registry entry for NCT05933174 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 483-participant average among 19 other Type2diabetes trials with a reported enrollment target (54% lower). The listed sponsor is Ian J. Neeland, MD, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type2diabetes appearing as the primary indexed condition, and to 2 interventions - of which Prompt-sheet is the first listed.
NCT05933174 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT05933174 about?
NCT05933174 is a clinical study titled "Promoting Alternatives to Sulfonylureas to Improve Patient Safety in Type 2 Diabetes". Sulfonylurea medications are unsafe for older patients with diabetes. They are associated not only with hypoglycemia, but also with falls and increased cardiovascular risk. Yet they continue to be prescribed frequently. Indeed, older adults with type 2 diabetes, who are especially prone to adverse e...
What is the current status of trial NCT05933174?
This trial is currently recruiting. It is a NA study. The enrollment target is 220 participants. The study started on 2023-10-01. Estimated completion is 2026-06-30.
What conditions does trial NCT05933174 study?
This clinical trial studies the following conditions: Type2diabetes.
What interventions are being tested in trial NCT05933174?
The interventions under investigation include: Prompt-sheet (OTHER), Usual education (OTHER).
Who is sponsoring clinical trial NCT05933174?
This trial is sponsored by Ian J. Neeland, MD, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05933174 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type2diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Fiber Supplementation in Heart Failure With Preserved Ejection Fraction (HFpEF)
RECRUITING · NA
-
Successfully Achieving and Maintaining Euglycemia During Pregnancy for Type 2 Diabetes Through Technology and Coaching
RECRUITING · NA
-
Feasibility and Adherence to a Technology-assisted Home-based Strength Training Program in Adults With Type 2 Diabetes Mellitus and Mild Cognitive Impairment
RECRUITING · NA
-
A Randomized Controlled Trial of Diabetes Screening Immediately Postpartum (DIP) and Follow Up PP CARE
RECRUITING · NA
-
Understanding and Addressing Risks of Low Socioeconomic Status and Diabetes for Heart Failure
RECRUITING · NA
-
The CARING Study: Creating and Restoring Health Through Nutrition Guidance
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.